CN1104896C - 作为细胞程序死亡抑制剂的RAR－γ拮抗剂配体或RAR－α激动剂配体 - Google Patents

作为细胞程序死亡抑制剂的RAR－γ拮抗剂配体或RAR－α激动剂配体 Download PDF

Info

Publication number
CN1104896C
CN1104896C CN96198770A CN96198770A CN1104896C CN 1104896 C CN1104896 C CN 1104896C CN 96198770 A CN96198770 A CN 96198770A CN 96198770 A CN96198770 A CN 96198770A CN 1104896 C CN1104896 C CN 1104896C
Authority
CN
China
Prior art keywords
disease
rar
naphthyl
benzoic acid
application according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN96198770A
Other languages
English (en)
Chinese (zh)
Other versions
CN1203529A (zh
Inventor
L·费苏斯
Z·索戴
U·雷赫尔特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Centre International de Recherches Dermatologiques Galderma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre International de Recherches Dermatologiques Galderma filed Critical Centre International de Recherches Dermatologiques Galderma
Publication of CN1203529A publication Critical patent/CN1203529A/zh
Application granted granted Critical
Publication of CN1104896C publication Critical patent/CN1104896C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
CN96198770A 1995-10-11 1996-10-08 作为细胞程序死亡抑制剂的RAR－γ拮抗剂配体或RAR－α激动剂配体 Expired - Fee Related CN1104896C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9511946A FR2739777B1 (fr) 1995-10-11 1995-10-11 Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose
FR95/11946 1995-10-11

Publications (2)

Publication Number Publication Date
CN1203529A CN1203529A (zh) 1998-12-30
CN1104896C true CN1104896C (zh) 2003-04-09

Family

ID=9483437

Family Applications (1)

Application Number Title Priority Date Filing Date
CN96198770A Expired - Fee Related CN1104896C (zh) 1995-10-11 1996-10-08 作为细胞程序死亡抑制剂的RAR－γ拮抗剂配体或RAR－α激动剂配体

Country Status (21)

Country Link
US (1) US6063797A (de)
EP (1) EP0854711B1 (de)
JP (1) JP3135267B2 (de)
KR (1) KR100300214B1 (de)
CN (1) CN1104896C (de)
AT (1) ATE212226T1 (de)
AU (1) AU695311B2 (de)
BR (1) BR9611035A (de)
CA (1) CA2231558C (de)
DE (1) DE69618802T2 (de)
DK (1) DK0854711T3 (de)
ES (1) ES2172680T3 (de)
FR (1) FR2739777B1 (de)
HU (1) HUP9900037A3 (de)
NO (1) NO981652L (de)
NZ (1) NZ319647A (de)
PL (1) PL186821B1 (de)
PT (1) PT854711E (de)
RU (1) RU2191008C2 (de)
TR (1) TR199800644T2 (de)
WO (1) WO1997013506A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10158192A (ja) 1996-10-03 1998-06-16 Eisai Co Ltd 移植片対宿主疾患（ｇｖｈｄ）の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物
FR2776511B1 (fr) * 1998-03-31 2001-05-11 Galderma Rech Dermatologique Utilisation dans ou pour la preparation d'une composition d'au moins un inhibiteur de l'activite de l'acide retinoique
IL142094A0 (en) * 1998-09-29 2002-03-10 Gamida Cell Ltd Methods of controlling proliferation and differentiation of stem and progenitor cells
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
US6713515B2 (en) * 2000-09-13 2004-03-30 Bristol Myers Squibb Company Retinoic acid receptor antagonists as promoters of angiogenesis
IL152904A0 (en) * 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
EP1465982A4 (de) * 2002-01-25 2006-06-07 Gamida Cell Ltd Verfahren zur expansion von stamm- und vorläuferzellen und damit erhaltene expandierte zellpopulationen
WO2006030442A2 (en) * 2004-09-16 2006-03-23 Gamida-Cell Ltd. Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
RU2007120254A (ru) * 2004-12-17 2009-01-27 Вайет (Us) Новые способы применения агонистов эстрогена бета
KR100798853B1 (ko) * 2005-02-15 2008-01-28 (주)한국스티펠 레티노이드를 유효성분으로 하는 백반증 예방 및 치료용 약학적 조성물
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
US8082730B2 (en) * 2008-05-20 2011-12-27 Caterpillar Inc. Engine system having particulate reduction device and method
GB0915196D0 (en) 2009-09-01 2009-10-07 King S College London Therapeutic compounds and their use
CN111773213B (zh) * 2010-09-01 2023-02-24 托马斯杰弗逊大学 用于肌肉修复和再生的组合物和方法
WO2013121426A1 (en) 2012-02-13 2013-08-22 Gamida-Cell Ltd. Culturing of mesenchymal stem cells
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
US9861640B2 (en) 2013-06-10 2018-01-09 Kemphys Ltd. Medicament for treatment of Alzheimer's disease
WO2016144976A1 (en) * 2015-03-09 2016-09-15 Kings College London Combination therapy with rar alpha agonists for enhancing th1 response
EP3277272B1 (de) 2015-03-31 2021-08-04 Syros Pharmaceuticals, Inc. Verfahren zur stratifizierung von patienten zur behandlung mit retinsäurerezeptoragonisten
US20190112272A1 (en) * 2016-04-07 2019-04-18 High Force Research Limited Synthetic retinoids for use in rar mediated conditions
KR20240157122A (ko) 2016-04-08 2024-10-31 사이로스 파마수티컬스, 인크. Aml 및 mds 치료용 rara 효능제

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0658553A1 (de) * 1993-12-15 1995-06-21 Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) Polycyclische aromatische Verbindungen, pharmazeutische Zubereitungen die diese enthalten und deren Anwendungen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780676A (en) * 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
US5399586A (en) * 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
FR2722985B1 (fr) * 1994-07-27 1996-09-13 Cird Galderma Nouvelles compositions a base d'un melange synergetique entre au moins un ligand specifique des rxrs et au moins un ligand specifique de rar-x ou de vdr, et leurs utilisations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0658553A1 (de) * 1993-12-15 1995-06-21 Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) Polycyclische aromatische Verbindungen, pharmazeutische Zubereitungen die diese enthalten und deren Anwendungen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEUKEMIA 8(增刊3) 1994-01-01 R.S.GILL等"SOLID TUMOR TREATMENT WORKSHOP SUMMARY" *

Also Published As

Publication number Publication date
NO981652L (no) 1998-06-10
ES2172680T3 (es) 2002-10-01
CA2231558C (fr) 2003-05-27
DK0854711T3 (da) 2002-03-25
HUP9900037A2 (hu) 1999-04-28
EP0854711A1 (de) 1998-07-29
HUP9900037A3 (en) 1999-11-29
DE69618802T2 (de) 2002-11-14
CA2231558A1 (fr) 1997-04-17
KR100300214B1 (ko) 2001-11-22
PL326162A1 (en) 1998-08-31
JPH11500448A (ja) 1999-01-12
NO981652D0 (no) 1998-04-08
WO1997013506A1 (fr) 1997-04-17
NZ319647A (en) 2000-06-23
AU7221096A (en) 1997-04-30
FR2739777A1 (fr) 1997-04-18
US6063797A (en) 2000-05-16
RU2191008C2 (ru) 2002-10-20
JP3135267B2 (ja) 2001-02-13
ATE212226T1 (de) 2002-02-15
BR9611035A (pt) 1999-07-06
PL186821B1 (pl) 2004-03-31
AU695311B2 (en) 1998-08-13
TR199800644T2 (xx) 1998-07-21
CN1203529A (zh) 1998-12-30
FR2739777B1 (fr) 1997-11-14
DE69618802D1 (de) 2002-03-14
KR19990064204A (ko) 1999-07-26
EP0854711B1 (de) 2002-01-23
PT854711E (pt) 2002-05-31

Similar Documents

Publication Publication Date Title
CN1203529A (zh) 作为细胞程序死亡抑制剂的RAR-γ拮抗剂配体或RAR-α激动剂配体
CN1121857C (zh) RAR－γ特异性激动剂配体用于提高细胞程序死亡率
Nagpal et al. Recent developments in receptor-selective retinoids
US20180008629A1 (en) Compositions and Methods for Treating NLRP3 Inflammasome-Related Diseases and Disorders
Romoser et al. Quantum dots trigger immunomodulation of the NFκB pathway in human skin cells
DE69431801T2 (de) Hemmung der stickstoffoxid bildung durch retinoinsaüre
MX2014013925A (es) Metodo para identificar ligandos del receptor ahr que tienen actividad sebosupresora terapeutica, y los ligandos.
Rabolli et al. Lung fibrosis induced by crystalline silica particles is uncoupled from lung inflammation in NMRI mice
DE69916496T2 (de) Zusammensetzung und verfahren
Wauben-Penris et al. Immunomodulatory effects of tretinoin in combination with clindamycin
Huang et al. Framework Nucleic Acid Nanoparticles Ameliorate Achilles TENDINOPATHY Through Tissue Penetration and Dual Regulation of the PI3K/AKT and MAPK Signaling Pathways
JP7162693B1 (ja) 馬乳酒由来エクソソーム及びその使用
MXPA98002760A (en) Linking rar-gamma antagonist or rar-alpha agonist as inhibitor of the apopto
Bradshaw et al. Anti-inflammatory effects of the retinoids
US20090042958A1 (en) Composition and method for treating immune-mediated skin disorders
Howard et al. Structure–toxicity relationships of the tetramethylated tetralin and indane analogs of retinoic acid
Fretland et al. Leukotriene B4-induced granulocyte trafficking in guinea pig dermis: effect of second-generation leukotriene B4 receptor antagonists, SC-50605 and SC-51146
TWI740342B (zh) 胜肽ＣＰＰｅｃｐ二聚體用於治療皮膚炎之用途
Chen et al. Supranutritional dietary vitamin D3 promoted the skin wound healing in turbot, Scophthalmus maximus L.
MXPA98002761A (en) Use of a rar-gamma specific agonist ligand to increase the percentage of apopto
CN102824349A (zh) 丹参酮ⅱa在制备治疗银屑病药物中的应用
Cia et al. Uptake and esterification of vitamin A by RCS rat retinal pigment epithelial cells in primary culture
CN1921851A (zh) 甲硝唑在制备用于治疗皮肤炎症药物组合物中的用途
Sperner-Unterweger et al. Clozapine induced neutropenia as an effect of decreased cytokine release

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee